The Bahrain Oncology Centre (BOC) has achieved a significant milestone, becoming amongst the first centres in the world to offer ground-breaking CASGEVY (exagamglogene-autotemcel or ‘exa-cel’) gene therapy for sickle cell disease (SCD) and transfusion dependent thalassemia (TDT).
This achievement follows the BOC’s successful accreditation, recognising its adherence to international standards for bone marrow transplant and cell therapy services .
&uuid=(email))